MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 82.52 Billion KRW | 5.39% |
| 2022 | 78.29 Billion KRW | 1.27% |
| 2021 | 77.31 Billion KRW | -17.96% |
| 2020 | 94.24 Billion KRW | -19.53% |
| 2019 | 117.1 Billion KRW | 16.91% |
| 2018 | 100.16 Billion KRW | 16.73% |
| 2017 | 85.8 Billion KRW | 29.9% |
| 2016 | 66.05 Billion KRW | -25.84% |
| 2015 | 89.07 Billion KRW | 7.63% |
| 2014 | 82.76 Billion KRW | -6.07% |
| 2013 | 88.1 Billion KRW | 4.15% |
| 2012 | 84.59 Billion KRW | -1.27% |
| 2011 | 85.68 Billion KRW | 23.82% |
| 2010 | 69.19 Billion KRW | 8.4% |
| 2009 | 63.83 Billion KRW | 390.87% |
| 2008 | 13 Billion KRW | -33.91% |
| 2007 | 19.67 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 84.27 Billion KRW | -1.2% |
| 2024 Q1 | 85.29 Billion KRW | 3.37% |
| 2023 Q2 | 81.14 Billion KRW | 5.1% |
| 2023 FY | 82.52 Billion KRW | 5.39% |
| 2023 Q1 | 77.2 Billion KRW | -1.4% |
| 2023 Q4 | 82.52 Billion KRW | 1.59% |
| 2023 Q3 | 81.22 Billion KRW | 0.1% |
| 2022 Q2 | 74.84 Billion KRW | -5.27% |
| 2022 Q4 | 78.29 Billion KRW | 1.0% |
| 2022 Q1 | 79 Billion KRW | 2.19% |
| 2022 FY | 78.29 Billion KRW | 1.27% |
| 2022 Q3 | 77.52 Billion KRW | 3.58% |
| 2021 Q1 | 94.45 Billion KRW | 0.23% |
| 2021 Q2 | 90.45 Billion KRW | -4.23% |
| 2021 FY | 77.31 Billion KRW | -17.96% |
| 2021 Q4 | 77.31 Billion KRW | -11.43% |
| 2021 Q3 | 87.29 Billion KRW | -3.49% |
| 2020 FY | 94.24 Billion KRW | -19.53% |
| 2020 Q1 | 116.61 Billion KRW | -0.42% |
| 2020 Q4 | 94.24 Billion KRW | 12.44% |
| 2020 Q3 | 83.81 Billion KRW | -4.87% |
| 2020 Q2 | 88.1 Billion KRW | -24.45% |
| 2019 Q1 | 108.26 Billion KRW | 8.08% |
| 2019 Q4 | 117.1 Billion KRW | 2.24% |
| 2019 Q3 | 114.54 Billion KRW | 6.89% |
| 2019 Q2 | 107.16 Billion KRW | -1.02% |
| 2019 FY | 117.1 Billion KRW | 16.91% |
| 2018 Q1 | 88.82 Billion KRW | 3.51% |
| 2018 Q3 | 97.82 Billion KRW | 4.49% |
| 2018 Q4 | 100.16 Billion KRW | 2.39% |
| 2018 FY | 100.16 Billion KRW | 16.73% |
| 2018 Q2 | 93.61 Billion KRW | 5.4% |
| 2017 Q4 | 85.8 Billion KRW | 11.55% |
| 2017 Q3 | 76.92 Billion KRW | 17.98% |
| 2017 Q2 | 65.19 Billion KRW | -0.6% |
| 2017 Q1 | 65.59 Billion KRW | -0.71% |
| 2017 FY | 85.8 Billion KRW | 29.9% |
| 2016 FY | 66.05 Billion KRW | -25.84% |
| 2016 Q1 | 88.71 Billion KRW | -0.4% |
| 2016 Q2 | 84.47 Billion KRW | -4.78% |
| 2016 Q3 | 66.01 Billion KRW | -21.85% |
| 2016 Q4 | 66.05 Billion KRW | 0.06% |
| 2015 Q1 | 85.52 Billion KRW | 3.34% |
| 2015 Q2 | 83.59 Billion KRW | -2.26% |
| 2015 Q4 | 89.07 Billion KRW | 4.8% |
| 2015 FY | 89.07 Billion KRW | 7.63% |
| 2015 Q3 | 84.99 Billion KRW | 1.68% |
| 2014 Q2 | 82.57 Billion KRW | -6.8% |
| 2014 FY | 82.76 Billion KRW | -6.07% |
| 2014 Q4 | 82.76 Billion KRW | 3.94% |
| 2014 Q3 | 79.62 Billion KRW | -3.57% |
| 2014 Q1 | 88.59 Billion KRW | 0.56% |
| 2013 Q1 | 87.56 Billion KRW | 3.51% |
| 2013 Q3 | 86.72 Billion KRW | -5.35% |
| 2013 Q4 | 88.1 Billion KRW | 1.58% |
| 2013 FY | 88.1 Billion KRW | 4.15% |
| 2013 Q2 | 91.62 Billion KRW | 4.64% |
| 2012 Q4 | 84.59 Billion KRW | 0.0% |
| 2012 Q1 | 53.62 Billion KRW | 0.0% |
| 2012 FY | 84.59 Billion KRW | -1.27% |
| 2011 FY | 85.68 Billion KRW | 23.82% |
| 2011 Q3 | 55.36 Billion KRW | 6.12% |
| 2011 Q2 | 52.17 Billion KRW | -17.37% |
| 2011 Q1 | 63.14 Billion KRW | 0.0% |
| 2010 Q2 | 34.67 Billion KRW | -0.3% |
| 2010 Q1 | 34.78 Billion KRW | 0.0% |
| 2010 Q3 | 34.68 Billion KRW | 0.02% |
| 2010 FY | 69.19 Billion KRW | 8.4% |
| 2009 Q1 | 21.09 Billion KRW | 62.22% |
| 2009 FY | 63.83 Billion KRW | 390.87% |
| 2009 Q3 | 34.33 Billion KRW | 24.72% |
| 2009 Q2 | 27.52 Billion KRW | 30.49% |
| 2008 Q2 | 15.51 Billion KRW | 0.0% |
| 2008 Q3 | 14.45 Billion KRW | -6.84% |
| 2008 FY | 13 Billion KRW | -33.91% |
| 2008 Q4 | 13 Billion KRW | -10.05% |
| 2007 FY | 19.67 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -837.49% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 85.574% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 73.455% |
| HANDOK Inc. | 283.45 Billion KRW | 70.888% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -311.118% |
| Yuhan Corporation | -69.18 Billion KRW | 219.272% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 57.453% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 2338.86% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 84.066% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 354.441% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -9.046% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -124.012% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -228.656% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -837.49% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 151.624% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 58.934% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 51.727% |
| JW Holdings Corporation | 480.68 Billion KRW | 82.833% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 49.861% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -70111.199% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 46.544% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -3409.53% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -258.761% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 52.838% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -58.77% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -837.49% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 47.87% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 76.961% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 46.544% |
| Yuhan Corporation | -69.18 Billion KRW | 219.272% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 39.32% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -38.285% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 80.771% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 46.544% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 29.007% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -402.403% |
| CKD Bio Corp. | 143.29 Billion KRW | 42.413% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 28.903% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 442.953% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 284.468% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -3409.53% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 80.484% |
| Boryung Corporation | 187.72 Billion KRW | 56.043% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 214.866% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -9.046% |
| JW Lifescience Corporation | 26.09 Billion KRW | -216.282% |